^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Endometrial Cancer
    Drug:samotolisib (LY3023414) (mTOR inhibitor, PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Gynecol Oncol
    Title:

    Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma

    Published date:
    06/25/2021
    Excerpt:
    Our study aims to investigate whether PI3K/mTOR dual inhibitor LY3023414 has synergistic effects with carboplatin in suppressing endometrial cancer (EC)…Combined treatment of LY3023414 and carboplatin synergistically inhibited proliferation, colony formation, promoted apoptosis of EC cells...LY3023414 had synergistic anti-tumor effects with carboplatin in HEC-1A subcutaneous xenograft which harbors PIK3CA mutation.
    Secondary therapy:
    carboplatin
    DOI:
    10.1016/j.ygyno.2021.06.015